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Abstract: Purpose: Transcriptional enhancer factor 1-related (RTEF-1) also known as TEAD4 is expressed in ocular 
vascular endothelial cells and plays a role in the control of VEGF expression. Alternative processing of TEAD4 hnRNA 
results in different proteins able to stimulate or inhibit VEGF gene transcription. The purpose of this study is to test 
whether short peptide fragments (STY-RMR), representing functional domains of the inhibitory TEAD4216 isoform, can 
inhibit tumor as well as endothelial cell proliferation. 
Experimental Design: Cell proliferation was assessed using a colorimetric assay in cell lines incubated with STY-RMR, 
the amount of secreted VEGF within media was determined both in treated and control cell lines. 
Results: Significant dose dependent inhibition of cell proliferation was observed. Maximal inhibition of ocular melanoma 
(Mel 202 and Mel 207) cell proliferation was observed at a dose of 30 mg/100ml of STY-RMR (87% and 60% inhibition, 
respectively). At the same dose, more than 50% inhibition was observed in retinoblastoma and breast cancer cells (P 
<0.001). Significant inhibition of primate ocular endothelial cell proliferation (42% at 30 mg/100 ml (p < 0.001), and retinal 
pigment epithelial cells showed also a 75% inhibition (p = 0.007). Secreted VEGF was decreased in the media of all 
tested cell lines that had been exposed to STY-RMR. 
Conclusion: Functional short peptide domains derived from the TEAD4216 isoform may prove to be useful for treatment of 
ocular tumors and other VEGF dependent neovascular disease.  
Inhibition of proliferation and VEGF production within ocular endothelial cells indicate the potential of this agent to treat 
age-related macular degeneration (ARMD) and diabetic retinopathy (DR). 
Keywords: Ocular tumors, Age-related macular degeneration (ARMD), Diabetic retinopathy, STY-RMR, Endothelial 
cell. 
INTRODUCTION 
Solid tumors depend on the formation of new blood 
vessels from preexisting vessels to supply them with 
nutrients and oxygen in order to grow beyond a size of 
1–2 mm3 [1]. In addition to the need for an expanding 
vascular network, evidence suggests that some tumor 
cell proliferation can be directly influenced by VEGF 
auto-regulation. Angiogenesis is a complex multistep 
process which starts with vascular endothelial growth 
factor (VEGF) induced vasodilatation and increased 
vascular permeability of pre-existing capillaries, or 
post-capillary venules [2]. 
Transcriptional enhancer factor 1-related (TEAD4) 
is present within ocular vascular endothelial cells and  
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plays a role in the control of the transcription of the 
VEGF gene [3] Full-length TEAD4 is known to 
stimulate cell proliferation in vitro. In cancer biology, 
internal hypoxic conditions are a common feature of 
solid tumors [4-6], gene transcripts associated with 
cancer metastasis are up regulated under hypoxic 
conditions and hypoxic gene signatures are associated 
with poorer prognosis [7]. Hypoxia-induced genes like 
VEGF-A are set on initiating tumor vascularization [8]. 
TEAD4 plays an important role in transcriptional 
regulation of angiogenic genes in hypoxic endothelial 
cells and independent of HIF-1α [9]. However, other 
studies suggest that TEAD4 act via HIF-1 as a key 
regulator of angiogenesis in response to hypoxia [10]. 
We have previously shown that various TEAD4 
domain is the only domain present in the inhibitor 
TEAD4216 and absent in the stimulator TEAD4148, 
therefore we hypothesized that this small fragment of 
2    World Journal of Oncology Research, 2018, Vol. 5 Ahmed et al. 
26 amino acids may mediate this inhibitory effect. This 
STY domain was linked to a cell penetrating peptide 
motif (RMR) to test the potential of this agent to inhibit 
tumor cell proliferation in vitro. We have previously 
demonstrated isoforms (generated through alternative 
hnRNA splicing) may be stimulatory (TEAD4148) or 
inhibitory (TEAD4216) to cell proliferation. A Ser-Thr-Tyr 
(STY) that a variety of human tumors expressed 
isoforms of TEAD4, therefore our purpose was to test 
whether a short peptide fragment, representing 
functional domains of the 651 TEAD4216 isoform, can 
inhibit tumor and endothelial cell proliferation. 
METHODS 
A 26 amino acid sequence corresponding to a Ser-
Thr-Tyr domain within TEAD4216 (Figure 1), linked to a 
10 amino acid cell importation signal (RMR) was 
synthesized (GenScript NJ). Human ocular melanoma 
cells (Mel 270, Mel 202; a kind gift from Dr Bruce 
Ksander), retinoblastoma cells (Y79; ATTC, MD), 
primate retina/choroid ocular endothelial cells (RF/6A; 
ATCC, MD) and human retinal pigment epithelial cells 
(ARPE19; ATCC, MD), (CRL 1500 breast cancer cell 
line; ATCC, MD) were plated into 96 well plates and 
cultured for 24 h. Recombinant STY-RMR peptide was 
added to the cell culture media at various 
concentrations (10 to 30 mg /100ml). 
Cell proliferation was assessed at 72 hours using a 
colorimetric XTT assay (Roche Diagnostics, 
Indianapolis, and CN, USA). Cell proliferation was 
expressed as a percentage and compared with 
untreated control cell growth (n = 3).  
The amount of VEGF within media was determined 
by VEGF ELISA (R&D Systems, MN, USA) and 
compared between STY-RMR treated and controls  
(n = 3).  
RESULTS 
To test whether the STY domain alone (which is 
present within the TEAD4216 repressor isoform but 
absent from the TEAD4148 enhancer isoform) can 
mediate repressor activity we synthesized STY linked 
to a cell penetrating peptide derived from tat (RMR) 
(Gen Script NJ) (Figure 1). 
Transcription enhancer factor 1-related (TEAD4) is 
a member of the TEAD DNA binding domain family, 
and it is present within ocular vascular endothelial cells 
and plays a role in the control of VEGF expression. We 
have demonstrated that a variety of human tumors 
expressed isoforms of TEAD4 (Figure 2). 
Breast cancer cells (CRL 1500) showed a very 
significant inhibition of 87% (P= 0.000002) at (30 ug/ 
100 ul) compared with untreated controls, the  
 
Figure 1: The second STY domain is present within the TEAD4216 repressor isoform but absent from the TEAD4148 enhancer 
isoform. To test whether the STY domain alone can mediate repressor activity we synthesized STY linked to a cell penetrating 
peptide derived from tat (RMR). The STY domain is 26 amino acids and the RMR is 10 amino acids in length, making the STY-
RMR peptide 36 amino acids long. 
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mean results of 3 independent experiments are shown 
(±SEM) in (Figure 3), and the proliferation of 
retinoblastoma cells is also inhibited by STY-RMR 
peptide in a dose dependent manner. We observed 
85% inhibition at 30 mg /100ml which is statistically 
different from control experiments in the absence of 
STY-RMR (P= 0. 00003). Mean results of 3 
independent experiments are shown (±SEM)  
(Figure 4). A scrambled sequence of STY-RMR was 
tested as a control and it did not show any significant 
inhibition in Y79 retinoblastoma cells (Figure 5). 
STY-RMR can inhibit cell proliferation in two 
different ocular melanoma cell lines. Significant 
inhibition (P= 0.006) of 60% below control was also 
observed in Mel270 incubated at the same dose and 
inhibition was dose dependent (Figure 6a) and 87% 
inhibition was observed at 30 ug /100ml for the Mel 202 
 
Figure 2: Variety of human tumors expressed isoforms of TEAD4. 
 
 
Figure 3: Breast cancer cells (CRL 1500) showed a very significant inhibition of 87% (P= 0.000002) at (30 ug/ 100 ul) compared 
with untreated controls, the mean results of 3 independent experiments are shown (±SEM). 
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cells mean results of 3 independent experiments are 
shown (±SEM) (p = 0. 001) (Figure 6b).  
STY-RMR peptide can inhibit proliferation of ocular 
vascular endothelial (RF/6A) and retinal pigment 
 
Figure 4: We observed 85% inhibition in proliferation of retinoblastoma at 30 ug /100ml which is statistically different from 
control experiments in the absence of   STY-RMR (P= 0. 00003). Mean results of 3 independent experiments are shown 
(±SEM). 
 
Figure 5: Scrambled version was tested as a control and it did not show any significant inhibition in retinoblastoma (Y79). 
 
Figure 6(a): Significant inhibition (P= 0.006) of 60% below control was also observed in Mel 270 incubated at the same dose 
and inhibition was dose dependent. 
Ocular Tumor and Endothelial Cell Growth with a TEAD4216 Peptide Fragment World Journal of Oncology Research, 2018, Vol. 5    5 
epithelial cells (ARPE-19) (Figure 7a). A (42%, p= 0 
.001) inhibition of RF-6A (Figure 7b) and 75% inhibition 
of ARPE-19 cells was observed with 30 mg /100ml of 
STY-RMR (P = 0.007). A dose dependent response 
was also observed as inhibition of cell proliferation was 
obtained with 3ug/100ul of treatment. 
ELISA indicates that STY-RMR treatment is able to 
decrease secreted VEGF levels in ocular melanoma 
cell line 270. By STY-RMR peptide. We observed 81% 
reduction in VEGF levels (p= 0.01) at 30 mg / 100ml 
treatment (Figure 8). 
 
Figure 6(b): 87% inhibition was observed at 30 ug /100ml for the Mel 202 cells mean results of 3 independent experiments are 
shown  (±SEM) (p = 0. 001). 
 
Figure 7(a): STY-RMR peptide can inhibit proliferation of ocular vascular endothelial (RF/6A) and retinal pigment epithelial cells 
(ARPE-19). 
 
Figure 7(b): A (42%, p= 0 .001) inhibition of RF-6A and 75% inhibition of ARPE-19 cells was observed with 30 mg /100ml of 
STY-RMR (P = 0.007). A dose dependent response was also observed as inhibition of cell proliferation was obtained with 
3ug/100ul of treatment. 
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VEGF levels is inhibited in ARPE19 cells by STY-
RMR peptide (Figure 9). An 88% reduction compared 
to control was observed after treatment with  
30 mg /100ml (p= 0.05). 
Levels of secreted VEGF is lower in ocular retinal-
choroid derived vascular endothelial cells after 
treatment with STY-RMR peptide. We observed 80% 
inhibition of VEGF at 30mg/100ml treatment (p= 0.03) 
in (Figure 10). 
 
Figure 8: ELISA indicates that STY-RMR treatment is able to decrease secreted VEGF levels in ocular melanoma cell line 270. 
by STY-RMR peptide. We observed 81% reduction in VEGF levels (p= 0.01) at 30 mg / 100ml treatment. 
 
Figure 9: VEGF levels is inhibited in ARPE19 cells by STY-RMR peptide. An 88% reduction compared to control was observed 
after treatment with 30 mg /100ml (p= 0.05). 
 
Figure 10: Levels of secreted VEGF is lower in ocular retinal-choroidal derived vascular endothelial cells after treatment with 
STY-RMR peptide. We observed 80% at 30 mg /100ml treatment (p= 0.03). 
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We further tested the potential of this agent to inhibit 
a breast tumor cell line at a lower range of daily doses, 
we focused on breast cancer to optimize conditions of 
delivery and efficacy. 
A significant inhibitory effect could be achieved by 
much lower daily doses twice a day for 3 days  
(Figure 11), since breast cancer cell (CRL 1500) had 
9% inhibition at 0.1 ug/ 100ul (p= 0.02), and 27% 
inhibition at 0.2, 0.5, and 1 ug/100 ul) (p= 0.02, 0.017, 
0.02) respectively, however this inhibition was 
increased to 50% at (5 and 6 ug/100ul) with much 
higher significance (p= 0.00002, 0.0005), indicating 
that this factor may have similar metronomic effect 
observed for chemotherapeutic agents which can 
inhibit tumors either by high one shot or daily small 
doses due to thrompospondin release which is known 
to be an endogenous anti-angiogenic factor, however 
we cannot assume that the inhibitory effect of STY-
RMR given once is a cytotoxic one at the highest dose 
despite the observation of a potent cell death induction 
at ( 30ug/ 100 ul) since we have also observed a 
significant VEGF reduction at the previous dose. 
This inhibition in breast tumor cells was also 
associated with decreased VEGF levels by STY-RMR 
78% (p= 0.02) even at low concentration (0.1ug/100ul) 
(Figure 12). 
DISCUSSION 
Transcription enhancer factor 1-related (TEAD4) is 
a member of the TEAD DNA binding domain family, 
and it is present within ocular vascular endothelial cells 
and plays a role in the control of VEGF expression [3], 
it has been previously suggested that members of the 
TEAD family might play a role in mammary tumor 
genesis [11]. We have demonstrated that a variety of 
 
Figure 11: Significant inhibition in the proliferation of cancer breast cell due to VEGF reduction by STY-RMR incubated cancer. 
 
Figure 12: Significant inhibition of VEGF by STY-RMR incubated cancer breast cell. 
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human tumors expressed isoforms of TEAD4, therefore 
we were motivated to test the therapeutic potential of 
such isoforms to treat cancer. 
The full-length TEAD4 is known to stimulate cell 
proliferation in vitro, and we have shown that various 
TEAD4 isoforms (generated through alternative hnRNA 
splicing) may be stimulatory or inhibitory to cell 
proliferation. A Ser-Thr-Tyr (STY) domain is the only 
domain present in the inhibitor TEAD4216 isoform while 
absent in the stimulator TEAD4148, therefore we 
hypothesized that this small fragment of 26 amino 
acids mediates this inhibitory effect. This STY domain 
was linked to a cell penetrating peptide motif (RMR) to 
test the potential of this agent to inhibit tumor cell 
proliferation in vitro. 
The activity of several anti-angiogenic proteins such 
as Endostatin is mimicked by a 27-amino-acid peptide 
[12] and it is recently developed as Fc-Endostatin 
which showed similar inhibition activity to this tested 
peptide [13] indicating that short functional domains 
have therapeutic potential. 
Ocular melanoma and retinoblastoma (Rb) are 
intraocular tumors whose growth are influenced by 
concomitant expression of VEGF, it has been reported 
that the number of ocular micrometastasis is correlated 
with the levels of VEGF in the serum [14]. Avastin is 
known to suppress the growth and hepatic metastasis 
of uveal melanoma through VEGF inhibition therefore 
VEGF can be used as a prognostic factor for ocular 
melanoma [15] but not for retinoblastoma [16]. RF-6A 
(a retinal endothelial cell line) and ARPE-19 (a retinal 
pigment epithelium cell line) are ocular derived cell 
lines whose growth are VEGF-dependent [17]. 
Significant inhibition of cell proliferation was 
observed with this STY-RMR in several tumor cell 
lines. Dose dependent responses were noted, however 
the range of this inhibitory effect is tumor type and /or 
cell line specific We tested the potential of this agent to 
inhibit tumor cell lines at a lower range of daily doses, a 
very significant inhibitory effect could be achieved by 
much lower daily doses for 3 days indicating that this 
factor may have similar metronomic effect observed for 
chemotherapeutic agents which can inhibit tumors 
either by high single dose or daily small doses such as 
that observed with thrompospondin release [18-20]. 
An inhibitory effect on cell proliferation was noted 
with the STY-RMR peptide in human Y79 
retinoblastoma cells a suspension cell line. the effect 
was lost when the cells were exposed to the scrambled 
peptide at the same dose indicating that the sequence 
order of the STY domain is critical to the function. The 
efficacy of STY-RMR to inhibit tumor cells which are 
growing in suspension suggests this compound may 
prove to be therapeutic on metastatic cells in the 
circulation or non-solid cancers such as leukemia. 
We further questioned whether STY-RMR inhibits 
the levels of VEGF in the same studied cell lines 
(ocular melanoma, RF-6A, ARPE-19, and breast 
cancer). We observed a significant decrease of VEGF 
production within different cell lines which indicates the 
potential of this agent to treat angiogenic diseases. 
CONCLUSION 
We have demonstrated that a small peptide which 
contains the STY motif of the human TEAD4 protein, 
when linked with a cell penetration motif, is able to 
inhibit cell proliferation rates in a number of cell lines 
germane to human disease. This effect is associated 
with a decreased rate of VEGF synthesis and may 
prove therapeutically useful. 
FUNDING 
Clayton Foundation for Research; National 
Institutes of Health (R01 EY019042) 
REFERENCES 
[1] Folkman J. Angiogenesis: an organizing principle for drug 
discovery? Nat Rev Drug Discov. 2007; 6(4): 273-86. 
https://doi.org/10.1038/nrd2115 
[2] Moens S, Goveia J, Stapor PC, Cantelmo AR, Carmeliet P. 
The multifaceted activity of VEGF in angiogenesis - 
Implications for therapy responses. cytogfr. 2014.07.009. 
Epub 2014 Jul 23. 
[3] Appukuttan B, McFarland TJ, Davies MH, Atchaneeyasakul 
LO, Zhang Y, Babra B, Pan Y, Rosenbaum JT et al. Invest 
Ophthalmol Vis Sci 2007; 48(8): 3775-82. 
https://doi.org/10.1167/iovs.06-1172 
[4] Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, 
Donini A. Malignant ascites: pathophysiology and treatment. 
Int J Clin Oncol. 2012 Feb 18. 
[5] Xia Y, Choi HK, Lee K. Recent advances in hypoxia-
inducible factor (HIF) -1 inhibitors. Eur J Med Chem 2012; 
49: 24-40. 
https://doi.org/10.1016/j.ejmech.2012.01.033 
[6] Ramaekers CH, van den Beucken T, Meng A, Kassam S, 
Thoms J, Bristow RG, Wouters BG. Hypoxia disrupts the 
Fanconi anemia pathway and sensitizes cells to 
chemotherapy through regulation of UBE2T. Radiother Oncol 
2011; 101(1): 190-7. Epub 2011 Jun 29. 
https://doi.org/10.1016/j.radonc.2011.05.059 
[7] Toustrup K, Sorensen BS, Alsner J, Overgaard J. Hypoxia 
gene expression signatures as prognostic and predictive 
markers in head and neck radiotherapy. Semin Radiat Oncol 
2012; 22(2): 119-27. 
https://doi.org/10.1016/j.semradonc.2011.12.006 
Ocular Tumor and Endothelial Cell Growth with a TEAD4216 Peptide Fragment World Journal of Oncology Research, 2018, Vol. 5    9 
[8] Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 
2005; 69Suppl 3: 11-6. Epub 2005 Nov 21. 
https://doi.org/10.1159/000088479 
[9] Cuili Zhang a,b,c, QH. Song c, Jian Li c,*, Ye Tian 
a,d,*Retraction notice to "Hypoxia-induced expression of 
RTEF-1 (related transcriptional enhancer factor-1) in 
endothelial cells is independent of HIF-1 (hypoxia inducible 
factor-1)" Biochem Biophys Res Commun 2009; 381(3): 333-
338. 
https://doi.org/10.1016/j.bbrc.2009.02.083 
[10] Zhang C, Song QH, Li J, Tian Y. Hypoxia-induced 
expression of RTEF-1 (related transcriptional enhancer 
factor-1) in endothelial cells is independent of HIF-1 
(hypoxia-inducible factor-1). Biochem Biophys Res Commun. 
2009; 381(3): 333-8. Epub 2009 Feb 21. 
https://doi.org/10.1016/j.bbrc.2009.02.083 
[11] Maeda T, Maeda M, Stewart AF. TEF-1 transcription factors 
regulate activity of the mouse mammary tumor virus LTR. 
Biochem Biophys Res Commun 2002; 296(5): 1279-85. 
https://doi.org/10.1016/S0006-291X(02)02085-5 
[12] Tjin Tham Sjin RM, Satchi-Fainaro R, Birsner AE, 
Ramanujam VM, Folkman J, Javaherian K. A 27-amino-acid 
synthetic peptide corresponding to the NH2-terminal zinc-
binding domain of endostatin is responsible for its antitumor 
activity. Cancer Res. 2005; 65(9): 3656-63. 
https://doi.org/10.1158/0008-5472.CAN-04-1833 
[13] Lee TY, Tjin Tham Sjin RM, Movahedi S, Ahmed B, Pravda 
EA, Lo KM, Gillies SD et al. Linking antibody Fc domain to 
endostatin significantly improves endostatin half-life and 
efficacy. Clin Cancer Res 2008; 14(5): 1487-93. 
https://doi.org/10.1158/1078-0432.CCR-07-1530 
[14] Crosby MB, Yang H, Gao W, Zhang L, Grossniklaus HE. 
Serum vascular endothelial growth factor (VEGF) levels 
correlate with number and location of micrometastases in a 
murine model of uveal melanoma. Br J Ophthalmol 2011; 
95(1): 112-7. 
https://doi.org/10.1136/bjo.2010.182402 
[15] Schuster C1,2, Akslen LA1,3, Stokowy T4,5, Straume O1,2. 
Predictive value of angiogenic proteins in patients with 
metastatic melanoma treated with bevacizumab 
monotherapy. 2018; 18.  
https://doi.org/10.1002/cjp2.116 
[16] Areán C, Orellana ME, Abourbih D, Abreu C, Pifano I, 
Burnier MN Jr. Expression of vascular endothelial growth 
factor in retinoblastoma. Arch Ophthalmol 2010; 128(2): 223-
9. 
https://doi.org/10.1001/archophthalmol.2009.386 
[17] Obert E, Strauss R, Brandon C, Grek C, Ghatnekar G, 
Gourdie R, Rohrer B. Targeting the tight junction protein, 
zonula occludens-1, with the connexin43 mimetic peptide, 
αCT1, reduces VEGF-dependent RPE pathophysiology. J 
Mol Med (Berl) 2017; 95(5): 535-552.  
https://doi.org/10.1007/s00109-017-1506-8 
[18] Matsuki K, Tanabe A, Hongo A, Sugawara F, Sakaguchi K, 
Takahashi N et al. Anti-angiogenesis effect of 3'-
sulfoquinovosyl-1'-monoacylglycerol via up regulation of 
thrombospondin 1. Cancer Sci 2012; 103(8): 1546-52.  
https://doi.org/10.1111/j.1349-7006.2012.02333.x 
[19] Maloney SL, Sullivan DC, Suchting S, Herbert JM, Rabai EM, 
Nagy Z, Barker J et al. Induction of thrombospondin-1 
partially mediates the anti-angiogenic activity of 
dexrazoxane. Br J Cancer 2009; 101(6): 957-66.  
https://doi.org/10.1038/sj.bjc.6605203 
[20] Ooyama A, Oka T, Zhao HY, Yamamoto M, Akiyama S, 
Fukushima M. Anti-angiogenic effect of 5-Fluorouracil-based 
drugs against human colon cancer xenografts. Cancer Lett 
2008; 267(1): 26-36. 
https://doi.org/10.1016/j.canlet.2008.03.008 
 
Received on 13-07-2018 Accepted on 25-09-2018 Published on 10-10-2018 
 
http://dx.doi.org/10.15379/2413-7308.2018.05.01 
© 2018 Ahmed et al.; Licensee Cosmos Scholars Publishing House. 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, 
provided the work is properly cited. 
 
